InsiderSignal.AI

InsiderSignal.ai

INSM - Insmed Inc

Insider Sale by Lewis William (Chair, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Lewis William, serving as Chair, CEO at Insmed Inc (INSM), sold 10,699 shares at $143.52 per share, for a total transaction value of $1,535,542.00. Following this transaction, Lewis William now holds 535,109 shares of INSM.

This sale represents a 2.00% decrease in Lewis William's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, March 19, 2026 and publicly disclosed via SEC Form 4 filing on Friday, March 20, 2026, 1 day after the trade was made.

Insmed Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Lewis William

Chair, CEO

William H. Lewis is the Chair and Chief Executive Officer of Insmed Incorporated (INSM), a biopharmaceutical company focused on serious and rare diseases. He joined Insmed in September 2012 as President and CEO and a director, becoming Chair of the Board in November 2018.[[1]](https://fintool.com/app/research/companies/INSM/people/william-h-lewis)[[2]](https://insmed.com/company/management-team/william-h-lewis-j-d-m-b-a/) Under his leadership, Insmed achieved accelerated approval for ARIKAYCE® in 2018 for refractory nontuberculous mycobacterial (NTM) lung disease, advanced its pipeline including brensocatib NDA priority review, and expanded internationally to Europe and Japan.[[1]](https://fintool.com/app/research/companies/INSM/people/william-h-lewis)[[3]](https://pharmaboardroom.com/interviews/william-h-lewis-chairman-ceo-insmed/) Lewis, aged 56, holds a B.A. cum laude from Oberlin College, an M.B.A., and a J.D. with Honors from Case Western Reserve University.[[1]](https://fintool.com/app/research/companies/INSM/people/william-h-lewis)[[2]](https://insmed.com/company/management-team/william-h-lewis-j-d-m-b-a/) His career highlights include co-founding Aegerion Pharmaceuticals (2005–2011), where he served as President and CFO, leading to a successful IPO in 2010; prior investment banking roles at JPMorgan Chase, Robertson Stephens, and Wells Fargo; and U.S. Foreign Service (1989–1992).[[1]](https://fintool.com/app/research/companies/INSM/people/william-h-lewis)[[2]](https://insmed.com/company/management-team/william-h-lewis-j-d-m-b-a/)[[4]](https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-appoints-william-h-lewis-jd-mba-chair-its) He currently chairs the board of NewAmsterdam Pharma (Nasdaq: NAMS).[[1]](https://fintool.com/app/research/companies/INSM/people/william-h-lewis)[[2]](https://insmed.com/company/management-team/william-h-lewis-j-d-m-b-a/)[[4]](https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-appoints-william-h-lewis-jd-mba-chair-its)

View full insider profile →

Trade Price

$143.52

Quantity

10,699

Total Value

$1,535,542.00

Shares Owned

535,109

Trade Date

Thursday, March 19, 2026

4 days ago

SEC Filing Date

Friday, March 20, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Insmed Inc

Company Overview

No company information available
View news mentioning INSM

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4948659

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime